Study of Sacituzumab Govitecan Versus Standard of Care in Participants With Previously Treated Extensive Stage Small Cell Lung Cancer

The goal of this clinical study is to learn more about the study drug sacituzumab govitecan (SG; Trodelvy®; GS-0132; IMMU 132), versus standard of care (SOC) in participants with previously treated extensive stage small cell lung cancer (ES-SCLC). The primary objectives of this study are to compare the effect of SG to SOC on overall survival (OS).

Trial Details

NCT ID
NCT06801834
Phase
PHASE3
Sponsor
Gilead Sciences
Status
RECRUITING
Cancer Type
Lung Cancer
Interventions
  • Sacituzumab Govitecan (SG)
  • Topotecan
  • Amrubicin (Japan only)
  • Lurbinectedin (regions/countries where approved and available)
Locations (sample)
  • Hot Springs, Arkansas, United States|34.5037,-93.05518
  • Anaheim, California, United States|33.83529,-117.9145
  • Miami, Florida, United States|25.77427,-80.19366
  • Hinsdale, Illinois, United States|41.80086,-87.93701
  • Springfield, Illinois, United States|39.80172,-89.64371

Key Eligibility Criteria

  • Histologically confirmed diagnosis of SCLC.
  • Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1.
  • Measurable disease by computed tomography (CT) or magnetic resonance imaging (MRI) as assessed by investigator per RECIST v1.1 criteria.
  • Documentation of radiological disease progression after 1 prior line of platinum-containing chemotherapy (defined as at least 2 cycles of treatment…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lung Cancer Trials on Trialify →